COVID-19 in Patients With Gynecologic Cancer: A Report From the COVID-19 and Cancer Consortium

Authors

• Alaina J Brown
• Chih-Yuan Hsu
• Aleenah Mohsin
• Lauren S Prescott
• Alicia Beeghly
• Erika Ruiz-Garcia
• Diana Vilar-Compte
• José Antonio García-Gordillo
• Clara Hwang, Henry Ford HealthFollow
• Miriana Hijaz, Henry Ford HealthFollow
• Thomas Buekers, Henry Ford HealthFollow
• Sunny R. K Singh, Henry Ford HealthFollow
• Trisha M Wise-Draper
• Elizabeth K Ferrara
• Rana R McKay
• Archana Ajmera
• Melissa Mariano
• Padmanabh Bhatt
• Gayathri Nagaraj
• Matthew Puc
• Jonathan A Cosin
• Babar Bashir
• Karen Russell
• Susan Halabi
• Hannah McManus
• Melissa K Accordino
• Blanche H Mavromatis
• Monika Joshi
• Hyma V Polimera
• Salvatore A Del Prete
• Suzanne J Rose
• Suki Subbiah
• Bryan A Faller
• Abdul Hai Mansoor
• Marc Eid
• Sanjay Mishra
• Roisin E O'Cearbhaill
• Marta A Crispens
• Yu Shyr
• Jeremy L Warner

Recommended Citation

Brown AJ, Hsu CY, Mohsin A, Prescott LS, Beeghly A, Ruiz-Garcia E, Vilar-Compte D, García-Gordillo JA, Hwang C, Hijaz M, Buekers T, Singh SRK, Wise-Draper TM, Ferrara EK, McKay RR, Ajmera A, Mariano M, Bhatt P, Nagaraj G, Puc M, Cosin JA, Bashir B, Russell K, Halabi S, McManus H, Accordino MK, Mavromatis BH, Joshi M, Polimera HV, Del Prete SA, Rose SJ, Subbiah S, Faller BA, Mansoor AH, Eid M, Mishra S, O’Cearbhaill RE, Crispens MA, Shyr Y, Warner JL. Covid-19 in Patients with Gynecologic Cancer: A Report from the Covid-19 and Cancer Consortium. JCO Oncol Adv. 2026;3(1).

Document Type

Article

Publication Date

1-3-2026

Publication Title

JCO Oncol Adv

Abstract

PURPOSE: Limited information exists regarding outcome severity among gynecologic cancer patients with SARS-CoV-2 infection. The objective of this study was to describe patient, cancer, and COVID-19 characteristics, and to identify factors associated with COVID-19 severity.

METHODS: Gynecologic cancer patients with SARS-CoV-2 infection were identified from the international COVID-19 and Cancer Consortium registry. We estimated odds ratios (ORs) for associations with severity of COVID-19 outcomes. Multivariable models included adjustment for age, race, cancer status, and time period of COVID-19 diagnosis.

RESULTS: Of 920 patients, 438 patients (48%) had endometrial, 249 (27%) had ovarian, 198 (22%) had cervical, and 44 (5%) had vulvar/vaginal cancers. Most were from the United States (86%) and non-Hispanic White (48%). Median age was 62 years (IQR, 52-71). When diagnosed with COVID-19, 457 (49%) patients were in remission and 343 (37%) had active disease. Outcomes included hospitalization in 452 patients (49%), intensive care unit admittance in 107 patients (12%), mechanical ventilation in 70 patients (8%), and death within 30 days of testing positive for SARS-CoV-2 in 91 patients (10%). In multivariable models, increasing age (adjusted OR, 1.35 [95% CI, 1.23 to 1.49]) and non-Hispanic Black race (adjusted OR, 1.75 [95% CI, 1.24 to 2.48]) were associated with increased COVID-19 severity, as were cardiac (adjusted OR, 1.85 [95% CI, 1.36 to 2.52]), pulmonary (adjusted OR, 1.58 [95% CI, 1.12 to 2.22]), and renal (adjusted OR, 2.18 [95% CI, 1.48 to 3.19]) comorbidities. Patients in remission < 5 years had decreased COVID-19 severity (adjusted OR, 0.60 [95% CI, 0.42 to 0.87]). Other cancer characteristics associated with increased severity included progression (adjusted OR, 2.91 [95% CI, 1.92 to 4.40]), stage (adjusted OR, 1.57 [95% CI, 1.11 to 2.22]), and metastatic disease (adjusted OR, 1.60 [95% CI, 1.10 to 2.34]).

CONCLUSION: Patients with gynecologic cancer experience significant morbidity and mortality related to infection with SARS-CoV-2. Age, race, cancer status, comorbidities, and COVID-19 complications were associated with more severe COVID-19 outcomes.

PubMed ID

42676975

Volume

3

Issue

1